All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells

Leukemia Research

Volumn 28, Issue 3, 2004, Pages 243-248

  Bairey, O ^a   Boycov, O ^a,b   Kaganovsky, E ^a,b   Zimra, Y ^a   Shaklai, M ^a   Rabizadeh, E ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Angiogenesis; Apoptosis; Chronic lymphocytic leukemia; VEGF; VEGFR 1; VEGFR 2; VEGFR 3

Indexed keywords

CD19 ANTIGEN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; B CHRONIC LYMPHOCYTIC LEUKEMIA; CELL ISOLATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOCYTOCHEMISTRY; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MALE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 0346365282     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00256-X     Document Type: Article

References (25)

1. Reed J.C. Molecular biology of chronic lymphocytic leukemia: implication for therapy. Semin. Haematol. 35:1998;3-13.
2. Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer. Res. 60:2000;293-312.
3. Gerber H.P., Dixit V., Ferrara N. Vascular endothelial growth factor induces expression of the anti-apoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 273:1998;13313-13316.
4. Nor J.E., Christensen J., Mooney D.J., Polverini P.J. Vascular endothelial growth factor (VEGF)- mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 154:1999;375-384.
5. Chen H., Treweeke A.T., West D.C., Kathleen J.T., Cawley J.C., Zuzel M., Toh C.H. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood. 96:2000;3181-3187.
6. Bairey O., Zimra Y., Shaklai M., Rabizadeh E. Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukemia. Br. J. Haematol. 113:2001;400-406.
7. Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin. Thromb. Hemost. 26:2000;561-569.
8. Gerwins P., Skoldenberg E., Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelium growth factors and their receptors in angiogenesis. Crit. Rev. Oncol. Hematol. 34:2000;185-194.
9. Karkkainen M.J., Petrova T.V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene. 1:2000;5598-5605.
10. Ziegler B.L., Valtieri M., Almeida Porada G., De Maria R., Muller R., Masella B., Gabbianelli M., Casella I., Pelosi E., Bock T., Zanjani E.D., Peschle C. KDR receptor: a key marker defining hematopoietic stem cells. Science. 285:1999;1553-1558.
11. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating J.M., O'Brien S., Rai K.R. National Cancer Institute sponsored working group guidelines for chronic lymphocytic leukemia-revised guidelines for diagnosis and treatment. Blood. 87:1996;4990-4997.
12. Rai K., Sawitsky A., Cronkite E., Chanana A.D., Levy R.N., Pasternak B. Clinical staging of chronic lymphocytic leukemia. Blood. 46:1975;219-234.
13. Molica S., Vitelli G., Levato D., Ricciotti A., Digiesi G. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblast growth factor in early B-cell chronic lymphocytic leukemia. Br. J. Cancer. 86:2002;31-35.
14. Molica S., Vacca A., Ribatti D., Cuneo A., Cavazzini F., Levato D., Vitelli G., Tucci L., Roccaro A.M., Dammacco F. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood. 100:2002;3344-3351.
15. Kay N.E., Bone N.D., Tschumper R.C., Howell K.H., Geyer S.M., Dewald G.W., Hanson C.A., Jelinek D.F. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia. 16:2002;911-919.
16. Aguayo A., Manshouri T., O'Brien S., Keating M., Beran M., Koller C., Kantarjian H., Rogers A., Albitar M. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk. Res. 25:2001;279-285.
17. Ferrajoli A., Manshouri T., Estrov Z., Keating M.J., O'Brien S., Lerner S., Beran M., Kantarjian H.M., Freireich E.J., Albitar M. High levels of vascular endothelial growth factor receptor-2 correlates with shortened survival in chronic lymphocytic leukemia. Clin. Cancer Res. 7:2001;795-799.
18. Gitay Goren H., Halaban R., Neufeld G. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem. Biophys. Res. Commun. 190:1993;702-708.
19. Takanami I., Tanaka F., Hashizume T., Kodaira S. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 17:1997;2811-2814.
20. Boocock C.A., Chamock Jones D.S., Sharkey A.M., McLaren J., Barker P.J., Wright K.A., Twentyman P.R., Smith S.K. Expression of vascular endothelial growth factor and its receptors Flt and KDR in ovarian carcinoma. J. Natl. Cancer Inst. 87:1995;506-516.
21. De Jong J.S., Van Diest P.J., Van Der Valk P., Baak J.P. Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I. An inventory in search of autocrine and paracrine loops. J. Pathol. 184:1998;44-52.
22. Carroll R.S., Zhang J., Bello L., Melnick M.B., Maruyama T., McL Black P. KDR activation in astrocytic neoplasm. Cancer. 86:1999;1335-1341.
23. Jackson M.W., Roberts J.S., Heckford S.E., Ricciardelli C., Stahl J., Horsfall D.J., Tilley W.D. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. 62:2002;854-859.
24. Dias S., Hattoti K., Heissig B., Zhu Z., Wu Y., Witte L., Hicklin D.J., Tateno M., Bohlen P., Moore M.A.S., Rafii S. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10857-10882.
25. Leenders W.O.J. Targeting VEGF anti-angiogenic and anti-tumour therapy: where are we now? Int. J. Exp. Pathol. 79:1998;339-346.